Furthermore, the combination of anti-PD1 therapy and METTL3 targeting led to synergistic antitumor efficacy in CRC.228 METTL3 was also reported to mediate the m6A methylation of the circRNA circIGF2BP3 (hsa_circ_0079587), boosting its circularization mediated via YTHDC1. The gene discussed is METTL3; the disease is colorectal carcinoma.